Terms: = Prostate cancer AND Neurokinin
14 results:
1. neurokinin-1 receptor drives PKCɑ-AURKA/N-Myc signaling to facilitate the neuroendocrine progression of prostate cancer.
Zhang XW; Li JY; Li L; Hu WQ; Tao Y; Gao WY; Ye ZN; Jia HY; Wang JN; Miao XK; Yang WL; Wang R; Mou LY
Cell Death Dis; 2023 Jun; 14(6):384. PubMed ID: 37385990
[TBL] [Abstract] [Full Text] [Related]
2. The In Vitro Pro-inflammatory Functions of the SP/NK1R System in prostate cancer: a Focus on Nuclear Factor-Kappa B (NF-κB) and Its Pro-inflammatory Target Genes.
Ebrahimi S; Erfani B; Alalikhan A; Ghorbani H; Farzadnia M; Afshari AR; Mashkani B; Hashemy SI
Appl Biochem Biotechnol; 2023 Dec; 195(12):7796-7807. PubMed ID: 37093533
[TBL] [Abstract] [Full Text] [Related]
3. Genetic validation of neurokinin 3 receptor antagonists for ischemic heart disease prevention in men - A one-sample Mendelian randomization study.
Schooling CM
EBioMedicine; 2022 Mar; 77():103901. PubMed ID: 35231698
[TBL] [Abstract] [Full Text] [Related]
4. Impact of the Oncology Care Model on Use of Supportive Care Medications During cancer Treatment.
Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
[TBL] [Abstract] [Full Text] [Related]
5. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract] [Full Text] [Related]
6. Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With cancer: A Retrospective Analysis.
Calcanes G; Vacirca JL
J Infus Nurs; 2019; 42(5):260-263. PubMed ID: 31464835
[TBL] [Abstract] [Full Text] [Related]
7. Investigational and experimental GnRH analogs and associated neurotransmitters.
Blumenfeld Z
Expert Opin Investig Drugs; 2017 Jun; 26(6):661-667. PubMed ID: 28441891
[TBL] [Abstract] [Full Text] [Related]
8. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
Okuyama A; Nakamura F; Higashi T
JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic Neuroendocrine Agonist and Antagonist Analogs of Hypothalamic Neuropeptides as Modulators of the Hypothalamic-Pituitary-Gonadal Axis.
Newton CL; Anderson RC; Millar RP
Endocr Dev; 2016; 30():106-29. PubMed ID: 26684214
[TBL] [Abstract] [Full Text] [Related]
10. Current and future applications of GnRH, kisspeptin and neurokinin B analogues.
Millar RP; Newton CL
Nat Rev Endocrinol; 2013 Aug; 9(8):451-66. PubMed ID: 23817290
[TBL] [Abstract] [Full Text] [Related]
11. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract] [Full Text] [Related]
12. Tachykinins and their receptors in human malignancies.
Palma C
Curr Drug Targets; 2006 Aug; 7(8):1043-52. PubMed ID: 16918332
[TBL] [Abstract] [Full Text] [Related]
13. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs.
Lang K; Drell TL; Lindecke A; Niggemann B; Kaltschmidt C; Zaenker KS; Entschladen F
Int J Cancer; 2004 Nov; 112(2):231-8. PubMed ID: 15352035
[TBL] [Abstract] [Full Text] [Related]
14. neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer.
Friess H; Zhu Z; Liard V; Shi X; Shrikhande SV; Wang L; Lieb K; Korc M; Palma C; Zimmermann A; Reubi JC; Büchler MW
Lab Invest; 2003 May; 83(5):731-42. PubMed ID: 12746482
[TBL] [Abstract] [Full Text] [Related]
